{"title": "Clinical characteristics of 101 non-surviving hospitalized patients with COVID-19: A single center, retrospective study", "doi": "10.1101/2020.03.04.20031039", "citation_id": "2020.03.04.20031039v2", "date": "2020-03-13", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.04.20031039", "abstract": "<p>Abstract\nRationale: COVID-19 have deprived many lives in Wuhan, China and caused global concerns. Few studies focused on clinical characteristics non-survivors hospitalized with COVID-19.  \nObjectives: We aimed to clarify the clinical characteristics of died patients with COVID-19 and tracked the causes of the rapid disease progression and death. \nMethods: 101 non-surviving patients with confirmed COVID-19 were included in this retrospective study. Clinical data were collected and compared between non-survivors who died within 3 days and after 3 days of admission. Multivariable regression analysis was used to analyze risk factors associated with rapid disease progression and death.\nMeasurements and Main Results: Among included patients, median age was 71 years (IQR, 59-80), 60 (59.41%) were men. 82 (81.19%) had one or more comorbidities including hypertension (59 [58.42%]), diabetes (22 [21.78%]) etc. 100 (99.01%) suffered respiratory failure, 53 (52.48%) developed acute cardiac injury, acute kidney and liver injury occurred in 23 (22.77%) and 18 (17.82%) patients, respectively. Multivariable regression analysis showed that elevated high sensitivity troponin I (OR 2.68, 95%CI 1.31-5.49, P=0.007), neutrophils (OR 1.14, 95%CI 1.01-1.28, P=0.033) and depressed oxygen saturation (OR 0.94, 95%CI 0.89-0.99, P=0.027) on admission were associated with rapid death of patients with COVID-19.\nConclusions: Older patients (&gt;70 years) with comorbidities had a steeply increased risk of death with COVID-19. Respiratory failure, acute cardiac and kidney injury played a crucial role in the death of patients. Elevated high sensitivity troponin, neutrophils and depressed oxygen saturation predicted the rapid death of patients.</p>", "twitter_description": "Abstract Rationale: COVID-19 have deprived many lives in Wuhan, China and caused global concerns. Few studies focused on clinical characteristics non-survivors hospitalized with COVID-19. Objectives: We aimed to clarify the clinical characteristics of died patients with COVID-19 and tracked the causes of the rapid disease progression and death. Methods: 101 non-surviving patients with confirmed COVID-19 were included in this retrospective study. Clinical data were collected and compared between non-survivors who died within 3 days and after 3 days of admission. Multivariable regression analysis was used to analyze risk factors associated with rapid disease progression and death. Measurements and Main Results: Among included patients, median age was 71 years (IQR, 59-80), 60 (59.41%) were men. 82 (81.19%) had one or more comorbidities including hypertension (59 [58.42%]), diabetes (22 [21.78%]) etc. 100 (99.01%) suffered respiratory failure, 53 (52.48%) developed acute cardiac injury, acute kidney and liver injury occurred in 23 (22.77%) and 18 (17.82%) patients, respectively. Multivariable regression analysis showed that elevated high sensitivity troponin I (OR 2.68, 95%CI 1.31-5.49, P=0.007), neutrophils (OR 1.14, 95%CI 1.01-1.28, P=0.033) and depressed oxygen saturation (OR 0.94, 95%CI 0.89-0.99, P=0.027) on admission were associated with rapid death of patients with COVID-19. Conclusions: Older patients (>70 years) with comorbidities had a steeply increased risk of death with COVID-19. Respiratory failure, acute cardiac and kidney injury played a crucial role in the death of patients. Elevated high sensitivity troponin, neutrophils and depressed oxygen saturation predicted the rapid death of patients.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nnone\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nall original data were saved in Renmin Hospital of Wuhan University, Wuhan, China", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031039v2.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031039v2", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.04.20031039v2.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.03.04.20031039.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. The copyright holder for this pre-print is the author. All rights reserved. The material may not be redistributed, re-used or adapted without the author's permission.", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.04.20031039v2", "access_rights": "restricted", "authors": ["Qiao Shi", "Kailiang Zhao", "Jia Yu", "Jiarui Feng", "Kaiping Zhao", "Xiaoyi Zhang", "Xiaoyan Chen", "Peng Hu", "Yupu Hong", "Man Li", "Fang Liu", "Chen Chen", "Weixing Wang"]}